Actuate Therapeutics wins FDA IND clearance for oral elraglusib cancer trial
PUBT · 05/11 11:04
Share
Listen to the news
- Actuate Therapeutics received FDA clearance of an IND for oral elraglusib.
- Phase 1/2 trial in advanced solid tumors planned to start in 2H 2026, targeting higher drug exposure than IV formulation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110700PRIMZONEFULLFEED9716826) on May 11, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending